Pfenex (PFNX) Tops Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/18/2026

1. SPY
2. EYPT
3. AWK
4. TSLA
5. NVDA
6. USO
7. ARGX
8. GNK
9. PLUR
10. RKLB

Go back to Pfenex (PFNX) Tops Q2 EPS by 4c

Pfenex (PFNX) Announces Positive Results for Px563L Anthrax Vaccine Study

August 8, 2016 7:32 AM EDT

Pfenex Inc. (NYSE: PFNX) announced positive immunogenicity and safety data from the Day 70 analysis of the Px563L anthrax vaccine study. The results demonstrate tolerable safety and significant immunogenicity after only 2 doses of Px563L.

"The Px563L data from the Day 70 analysis of the phase 1 study are very encouraging, with the vaccine being well-tolerated and affording potentially superior protection after only 2 doses," noted Dr. Hubert Chen, chief medical officer of Pfenex. Bertrand C. Liang, chief executive officer added, "These positive anthrax vaccine findings are a strong validation of our close... More

Pfenex (PFNX) Will Regain Full Rights to Lucentis Biosimilar PF582

August 8, 2016 7:31 AM EDT

Pfenex Inc. (NYSE : PFNX) announced that the company will regain the full rights to PF582, a biosimilar candidate to Lucentis, following our partner's strategic review of the current therapeutic focus of its biosimilar pipeline.

"With Pfenex regaining the rights to PF582 we are announcing the PF582 phase 1/2 safety and efficacy data which we believe highlights the significant value of the program," stated Bertrand C. Liang, chief executive officer of Pfenex. "We will consider strategic... More